Consortium will also look for lead drug candidates.

Beactica, GE Healthcare, and Uppsala University are collaborating to develop fragment-based drug discovery technology. The agreement also covers the identification of high-quality leads against an undisclosed protein target from Beactica’s pipeline.

The partnership combines GE Healthcare’s Biacore™ technology with Uppsala University’s enzymology technique using Beactica’s approach to fragment-based drug discovery. The parties will develop the next generation of Biacore surface plasmon resonance instruments and applications.

Beactica was spun out of Uppsala University in August 2006.



Previous articleEpiCept Abandons Drug Discovery Activities and Cuts Staff
Next articleScientists Create Technique to Screen Antibody Libraries against Large Antigen Libraries